Alkem Laboratories Ltd (ALKEM) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a solid quarter with a year-on-year revenue growth of approximately 11%, driven by strong performance in both its India and International businesses.
- The India business demonstrated robust growth, outperforming the Indian Pharmaceutical Market (IPM) by 100 basis points, with particularly strong performance in the chronic segment which grew 250 basis points ahead of the market.
- International sales grew by a notable 16% year-on-year, supported by favorable currency movements and continued growth in non-U.S. markets like Chile and Australia.
- While EBITDA margins remained healthy at 20.5%, net profit saw a significant decline of 21.7% year-on-year, which management attributed purely to higher tax provisions at the consolidated level.
- The company is facing a regulatory challenge with its Daman facility receiving an OAI status from the USFDA, though management has assured that product supplies to the U.S. market remain uninterrupted.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.